Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Chemotherapy

Rolapitant—a new and safer antiemetic agent

Chemotherapy-induced nausea and vomiting (CINV) is one of the most feared adverse effects of chemotherapy. Now, three trials, all coordinated by Lee Schwartzberg and Bernardo Rapoport, show that rolapitant is a novel, safe and effective agent for the prevention of CINV.

CINV is divided into an acute phase (the first 24 h after treatment initiation) and a delayed phase (24–120 h after treatment); serotonin is the main mediator of the acute phase reactions, whereas those that occur in the delayed phase are mediated by neurokinin-1 (NK-1) and substance P. Thus, current treatment guidelines for the prevention of CINV recommend the use of an NK-1 receptor antagonist, a serotonin receptor antagonist and dexamethasone. However, most NK-1 receptor antagonists interact with CYP3A4 and, therefore, affect the pharmacokinetics of drugs administered concomitantly.

Rolapitant is an NK-1 receptor antagonist with high affinity for the human NK-1 receptor that does not interact with CYP3A4. Its half-life is around 180 h and thus a single dose might be sufficient to prevent CINV. The aim of three phase III trials was to assess the safety and efficacy of rolapitant in combination with granisetron (a 5-HT3 receptor antagonist) and dexamethasone to prevent CINV induced by moderately emetic chemotherapy (MEC) and highly emetic chemotherapy (HEC). The MEC agents used were carboplatin, cyclophosphamide and irinotecan, among others. The HEC agents used were cisplatin, and anthracycline plus cyclophosphamide combinations.

Credit: cbenjasuwan/iStock/Thinkstock

In both the MEC and HEC settings, a significantly greater proportion of patients treated with rolapitant compared with placebo had no delayed-phase emesis, which addresses an unmet clinical need. In addition, patients receiving rolapitant who did not develop CINV in the acute phase were more likely to not develop CINV in the delayed phase.

“Rolapitant's long half-life offers us the opportunity to further explore dosing options—maybe it can be given the day before chemotherapy if that is more convenient for the patient,” says Rapoport. Schwartzberg concludes, “patients often believe that they are supposed to vomit on chemotherapy, but the reality is we have very good drugs to prevent this. Some patients will stop their treatment because of their CINV and that's the last thing we want.”

References

  1. Rapoport, B. L. et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 10.1016/S1470-2045(15)00035-2

  2. Schwartzberg, L. S. et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol. 10.1016/S1470-2045(15)00034-0

Download references

Authors

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Romero, D. Rolapitant—a new and safer antiemetic agent. Nat Rev Clin Oncol 12, 562 (2015). https://doi.org/10.1038/nrclinonc.2015.144

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2015.144

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing